Nanopublications

Matches in Nanopublications for { ?s ?p "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

Showing items 1 to 10 of 10 with 100 items per page.

NP591575.RAWl2GOWcAqvmmLprcoKu51b_C3y8enTAeeZmXkI6DoKI130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591575.RAWl2GOWcAqvmmLprcoKu51b_C3y8enTAeeZmXkI6DoKI130_provenance.
NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_provenance.
assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP591592.RAg9cekKkLJwFifuUhePFnvJ0SgBXTpgX9YGfKUUXiUuM130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591592.RAg9cekKkLJwFifuUhePFnvJ0SgBXTpgX9YGfKUUXiUuM130_provenance.
NP926673.RAWzoNSr03SiElTbk_oX4wV8g43yi-8HcQI8PDrNxzLYY130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP926673.RAWzoNSr03SiElTbk_oX4wV8g43yi-8HcQI8PDrNxzLYY130_provenance.
NP926671.RArWTz1hi8uC60jbqxq3OkJLceo06qGxtjP7jjSj3H8IE130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP926671.RArWTz1hi8uC60jbqxq3OkJLceo06qGxtjP7jjSj3H8IE130_provenance.
NP926674.RA8qzkvLXSqk9iDTTPDl_k9mIMXdUNOlWc-A7c7v6KorI130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP926674.RA8qzkvLXSqk9iDTTPDl_k9mIMXdUNOlWc-A7c7v6KorI130_provenance.